Product Information

GLEEVEC 400 MG TABLET is a brand product labeled by Novartis Pharmaceuticals Corporation, priced at $328.0342 per EA under NDC 00078064913. Its NADAC has been published 46 times since Oct 30, 2024.

The High Outlier badge above means this manufacturer's average price in the imatinib mesylate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

GLEEVEC 400 MG TABLET

imatinib mesylate
$328.0342per EA
High Outlier

Strength

400 mg/1

NDC

00078064913

Classification

Brand

Dosage Form

TABLET

Route

ORAL

Last Updated

10/30/2024

Active Ingredients

IMATINIB MESYLATE

Approval Type

New Drug (NDA)

FDA Application

NDA021588

On Market Since

12/23/2014

Pharmacological Classes

Bcr-Abl Tyrosine Kinase Inhibitors
Cytochrome P450 2D6 Inhibitors
Cytochrome P450 3A4 Inhibitors
Kinase Inhibitor

Price Statistics

The NADAC for GLEEVEC 400 MG TABLET has been published 46 times since Oct 30, 2024, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.

Current price$328.0342 per EA
All-time high$328.0342 (Sep 10, 2025)
All-time low$328.0342 (Oct 30, 2024)
52-week high$328.0342
52-week low$328.0342
Median price$328.0342
Average price$328.0342
Largest weekly change0.0% (Nov 6, 2024)
Weeks tracked46
Tracking sinceOct 30, 2024

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

0.0%

1Y

0.0%

3Y

N/A

5Y

N/A

All

0.0%

Generic Alternatives

The matcher finds 7 NADAC-published products sharing this drug's active ingredient, strength, and dosage form across 7 manufacturers (up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 99% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Frequently asked questions

What is the NADAC price of GLEEVEC 400 MG TABLET?

The current National Average Drug Acquisition Cost (NADAC) for GLEEVEC 400 MG TABLET, manufactured by Novartis Pharmaceuticals Corporation, is $328.0342 per EA (NDC 00078064913), effective Sep 10, 2025.

How has the price of GLEEVEC 400 MG TABLET changed over time?

Over the history we have for it, the NADAC for GLEEVEC 400 MG TABLET has held within roughly two percent of its current level. It has been tracked across 46 weekly CMS publications since Oct 30, 2024.

What are the highest and lowest recorded NADAC prices for GLEEVEC 400 MG TABLET?

Since Oct 30, 2024, the NADAC for GLEEVEC 400 MG TABLET has ranged from a low of $328.0342 (Oct 30, 2024) to a high of $328.0342 (Sep 10, 2025), with a median of $328.0342 per EA.

Are there cheaper alternatives to GLEEVEC 400 MG TABLET?

Yes. 7 NADAC-published products share the same active ingredient, strength, and dosage form. The lowest-priced option, IMATINIB MESYLATE 400 MG TAB, is $2.0356 per EA — about 99% below GLEEVEC 400 MG TABLET.

Who manufactures GLEEVEC 400 MG TABLET?

GLEEVEC 400 MG TABLET (NDC 00078064913) is labeled by Novartis Pharmaceuticals Corporation, and CMS classifies it as a brand product.